Post hoc analyses of SHIFT and PARADIGM‐HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: "Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial" by Bocchi et al. (9th October 2018) - Ramires, Felix J.A.; Martinez, Felipe; Gómez, Efraín A.; Demacq, Caroline; Gimpelewicz, Claudio R.; Rouleau, Jean L.; Solomon, Scott D.; Swedberg, Karl; Zile, Michael R.; Packer, Milton; McMurray, John J.V.